Key Points
- Enovis insider Oliver Engert bought 2,660 shares at an average price of $18.80, investing $50,008 and increasing his stake by 4.34% to 63,898 shares. The purchase followed several other insider buys in recent months.
- Enovis shares opened at $19.95, with a market capitalization of approximately $1.15 billion and a 12-month trading range of $18.52 to $34.28. The company recently exceeded quarterly EPS and revenue estimates, reporting $0.90 EPS and $582.78 million in revenue.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $40.38; institutional investors own 98.45% of the company’s stock.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert purchased 2,660 shares of the firm's stock in a transaction on Friday, September 4th. The stock was bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the completion of the purchase, the insider owned 63,898 shares of the company's stock, valued at approximately $1,201,282.40. This represents a 4.34% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Oliver Engert also recently made the following trade(s):
- On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The stock was purchased at an average price of $20.32 per share, for a total transaction of $49,946.56.
- On Thursday, September 3rd, Oliver Engert acquired 5,140 shares of Enovis stock. The shares were acquired at an average price of $19.46 per share, for a total transaction of $100,024.40.
- On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average cost of $20.92 per share, with a total value of $20,920.00.
- On Thursday, June 11th, Oliver Engert acquired 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00.
- On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average price of $23.00 per share, for a total transaction of $23,000.00.
Enovis Stock Up 7.5%
Shares of NYSE:ENOV opened at $19.95 on Wednesday. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -1.04 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 12-month low of $18.52 and a 12-month high of $34.28. The business's 50 day moving average is $25.42 and its 200 day moving average is $24.18.
Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the firm posted $0.79 EPS. Enovis's quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on ENOV shares. Weiss Ratings upgraded shares of Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Citizens Jmp dropped their target price on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a research report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 target price on Enovis in a research note on Tuesday, September 1st. UBS Group reaffirmed a "buy" rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Finally, Wells Fargo & Company dropped their price target on Enovis from $39.00 to $33.00 and set an "overweight" rating on the stock in a report on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Enovis currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.38.
Check Out Our Latest Analysis on ENOV
Institutional Trading of Enovis
Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System lifted its stake in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company's stock valued at $1,622,000 after buying an additional 621 shares in the last quarter. MGO One Seven LLC grew its holdings in Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company's stock valued at $202,000 after buying an additional 650 shares in the last quarter. Allworth Financial LP increased its holdings in Enovis by 59.7% during the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company's stock worth $36,000 after acquiring an additional 652 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after purchasing an additional 707 shares during the period. Finally, Empowered Funds LLC increased its stake in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after acquiring an additional 749 shares during the last quarter. Institutional investors own 98.45% of the company's stock.
About Enovis
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
